At this year's BIO conference, a palpable tension emerged over proposed US regulations that would sharply limit biotech deals with Chinese companies. Investors and executives argue that sweeping bans could undermine the ambitions of domestic entrepreneurs, who often rely on Chinese partners for manufacturing, funding, and early-stage research.
The debate centers on national security concerns versus the practical realities of a deeply interconnected industry. While some policymakers advocate for strict separation, many in the biotech ecosystem caution that such moves could backfire, cutting off access to cost-effective production capacity and slowing the development of new therapies.
Industry observers note that China has become a linchpin in the global biotech supply chain, particularly for small-molecule drugs and generic biologics. A blanket prohibition might force US startups to seek alternative partners in India or South Korea, but those options come with their own challenges, including longer timelines and different regulatory frameworks.
The discussions come amid broader geopolitical friction, with the US government weighing legislation similar to the BIOSECURE Act. Meanwhile, Chinese biotech firms are increasingly seeking domestic partnerships and funding, signaling a potential decoupling that could reshape the competitive landscape.
Against this backdrop, conference attendees stressed the need for targeted, risk-based regulations rather than across-the-board restrictions. The outcome of these policy debates could have lasting implications for drug development costs, innovation velocity, and patient access in both countries.